TSI Investor Profile: ABcann

Company: ABcann

Symbol: TSXV: ABCN | OTC: ABCCF

Country: Canada
Sector: Healthcare
Industry: Legal Cannabis
Established: 2012

https://www.abcann.ca/

ABcann

Featured Video

Company Brief

Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading  production yields in excess of 250 grams per sq. ft., double the industry average.

The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.

Summary

Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: 625 kilograms
Number of Patients: N/A
Headquarters: Napanee, Ontario

Financials (pro forma 09/30)

Cash on hand: $28.9mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A
EPS: N/A

Capital Structure (04/23/17)

Last Financing: 12.875mm shares at $0.80
Basic Shares: 97.20mm
Warrants: 39.71mm
Options: 9.41mm
Diluted Shares: 173.83mm

 

Highlights

 

  • Focus on pharmaceutical grade plant standardization
  • 94.7% customer retention rate
  • Organic production using exclusive, computer-controlled environmental system

 

Growth Strategy

 

  • Expand existing facility and construct 2nd facility targeting 40 kg/annum production capacity
  • Pursue global initiatives in Europe, Israel and Australia
  • Active discussions to license production to U.S. operators

 

Differentiators

 

  • Production through computer-controlled environmental systems
  • Industry-leading efficiency in terms of yield per square foot
  • Research partnership with University of Guelph

Exclusive Interview

Above Industry Average Yields


ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.


 

Strong Advisory Board Led by
the “Father of Cannabis Medicine”


Dr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.

Related Articles

ABcann to Raise $30 Million through Convertible Debentures

2017-11-27

ABcann Global Corporation (TSXV:ABCN) announces that it has entered into a binding interim agreement with respect to a proposed private placement of convertible senior unsecured debentures in the aggregate principal amount of $30,000,000.

ABcann Global Puts The 'Green' In Green Rush

2017-10-13 Bay Area Kid

Seekingalpha.com recently posted an in-depth article looking at ABcann Global (TSX.V: ABCN OTCQB: ABCCF) and how well positioned it is in this emerging market. It's a great read for those interested in this company that we've identified as one of Canada's Strongest Growers.

Canada's Licenced Producers of Medical Cannabis Form Retail Cooperative: Canadian Cannabis Co-op will provide investment, jobs and safe, regulated cannabis to Alberta and beyond

2017-10-05

Twelve of Canada's leading Licenced Producers of medical cannabis (including ABcann) today announced the creation of the Canadian Cannabis Co-op. The Co-op is prepared to make a significant investment in Alberta to create a turn-key retail solution to address the challenges of safe, regulated supply and socially-responsible cannabis retailing.